GLP-1 gotchas — the vertical-specific traps that will burn you

The plain-English version

A lot of marketing advice you'll read online is generic. "Use urgency!" "Show transformation!" "Compare against the competition!" Some of that is true for some categories. Almost none of it is safe in GLP-1 telehealth. The vertical has been specifically penalized for exactly those moves.

This lesson is a tour through the highest-frequency, highest-cost gotchas — what they are, who got penalized for them, and what to do instead.

Gotcha 1 — The "same as branded" trap

What it is: Saying or implying that a compounded GLP-1 product is "the same as" / "equivalent to" / "alternative to" Wegovy, Ozempic, Mounjaro, or Zepbound.

Who got penalized: Almost every company in the September 2025 and February 2026 FDA warning letter waves. Eight curated examples live in data/kb/regulatory/fda/.

Why it's tempting: It's the shortest path to communicating value. Patients already know the branded drugs. Saying "same as Wegovy for 80% less" is a one-sentence pitch.

Why it's penalized: Compounded products are not FDA-approved. Borrowing the brand-name drug's regulatory status (and its clinical trial data) is treated as deception under FDCA §502(bb).

What to do instead:

• Name the molecule, not the brand. "Compounded semaglutide" is fine. "Compounded version of Ozempic" is not.
• Lead with the clinician + the pharmacy partner, not the drug comparison.
• If discussing why someone might want a compounded option at all, use language about "different pathway" or "individualized preparation," not "alternative to."

Gotcha 2 — The "FDA-approved" slip

What it is: Calling a compounded preparation "FDA-approved" or "genuine, FDA-approved formulation."

Who got penalized: eDrugstore (warning letter 716505, Sept 2025). Direct quote: "eDrugstore guarantees that all Tirzepatide medications are genuine, FDA-approved formulations for maximum efficacy and safety." The phrase "FDA-approved" describing a compounded product was specifically cited.

Why it's tempting: "FDA-approved" reads as a credibility signal. Marketers reach for it without realizing it's false in this context.

Why it's penalized: Compounded drugs are categorically not FDA-approved. The phrase is a false claim, not just a misleading one.

What to do instead:

• "Compounded by a licensed 503A pharmacy."
• "Prepared under USP-797 sterile-compounding standards."
• "Prescribed by a US-licensed clinician."

These are real credibility signals you can actually claim.

Gotcha 3 — Clinical-trial claims for compounded products

What it is: Citing weight-loss percentages from Wegovy / Mounjaro trials in advertising for a compounded product.

Who got penalized: GLP-1 Solution (warning letter 715883, Sept 2025), among others. The specific concern: using STEP / SURMOUNT trial outcomes (which were done on the FDA-approved branded drugs) to imply the compounded product would deliver the same.

Why it's tempting: The numbers are dramatic ("up to 22% body weight loss"). They're the strongest performance claim in the category.

Why it's penalized: Clinical trial outcomes belong to the specific product tested. Borrowing them for a different (compounded) product is deceptive. It's analogous to citing a Toyota crash-test result while selling a Honda.

What to do instead:

• Don't quote percentage outcomes at all in compounded copy.
• Use language like "individual results vary" and stick to qualitative outcome descriptions.
• If outcome data exists for the compounded product specifically, cite it with full source attribution.

Gotcha 4 — "Skip the doctor visit"

What it is: Marketing the clinician interaction as a friction to be eliminated. "Get a prescription in minutes." "Skip the office visit." "Same-day approval."

Who got penalized: 24HrDoc (warning letter 717984, Feb 2026). The "24Hr" branding itself was treated as part of the violation.

Why it's tempting: Patient frustration with traditional primary care (months-long appointment lead times, weight-loss stigma) makes "fast and easy" feel like genuine relief.

Why it's penalized: 503A compounding is legally distinct from FDA- approved prescribing because each preparation is supposed to be individualized by a clinician based on a documented clinical need. Marketing that minimizes the clinician interaction undermines the legal basis for compounding at all.

What to do instead:

• Treat the clinician interaction as a feature: "A licensed clinician tailors dosing to your medical history."
• Talk about convenience post-evaluation: "Once your clinician approves your treatment plan, your medication ships discreetly."
• Make the evaluation step prominent in the funnel description.

Gotcha 5 — Before/after photos

What it is: Using transformation photos (especially as headline creative) and/or quantified weight-loss claims in testimonials.

Who got penalized: Lumimeds (warning letter 716510, Sept 2025). Specifically cited: "Sarah lost 35 lbs in 12 weeks" type narratives without typical-results disclosure.

Why it's tempting: Before/after is the highest-CTR creative format in weight-loss DTC. Quantified outcomes anchor expectation.

Why it's penalized: FTC Endorsement Guides (16 C.F.R. Part 255) require testimonials to either reflect typical results or disclose what is typical. For compounded products, no "typical result" can be established because there isn't substantiating data.

What to do instead:

• Use clinician-context imagery and lifestyle imagery, not body transformation.
• Frame patient stories around experience ("the clinician walked me through what to expect each month") not outcome.
• If quantified outcomes appear at all, use generalized population context with full source attribution.

Gotcha 6 — Side-by-side pricing tables

What it is: Comparing compounded semaglutide pricing line-by-line against Wegovy / Mounjaro list prices.

Who got penalized: SimpleRx (warning letter 715874, Sept 2025). The format itself was cited, separately from the price claims within.

Why it's tempting: Price is the strongest differentiator for many compounded competitors. Side-by-side tables make the differentiation obvious.

Why it's penalized: When you put two products next to each other in a price comparison, you imply they're substitutable. That's the "sameness with branded" violation in table form.

What to do instead:

• Discuss price in absolute terms only: "$X/month, includes consultation, medication, and follow-ups."
• If discussing access barriers, do so without naming a branded comparator: "Many patients face insurance or supply constraints; we offer a different pathway."

What to remember

The pattern across all six gotchas is the same: whatever feels like the obvious marketing move in this category is probably the move the FDA has already penalized. Treat your first instinct as something to question, not act on.

The compliance pipeline catches most of these automatically. But "catches them" means "rejects the variant after it's been generated" — which costs LLM tokens, copywriter cycles, and review- queue time. Better to write copy that never trips compliance in the first place. That starts with knowing the gotchas before you write.

What to do next

• Read every file in data/kb/regulatory/fda/. They're short, specific, and based on real warning letters.
• Read Compliance basics for the broader three-regime picture.
• Read the Competitive playbook for what to do instead of each gotcha — i.e., the moves that win.